Drug Trial Radar · NCT01421186
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Jul 2011
Primary completion
Aug 2020
Study completion Aug 2020
Sponsor
- Lead sponsor
- MorphoSys AGIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with relapsed/refractory multiple myeloma in combination with standard therapy.
Conditions
- Multiple Myeloma
Interventions
MOR03087 phase 1 dose escalationDrug
Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle. In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.
MOR03087Drug
MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
DexamethasoneDrug
Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
PomalidomideDrug
Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
LenalidomideDrug
Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087Time frame: First cycle of treatment
- Number of Participants Who Develop Anti-MOR03087 AntibodiesTime frame: during treatment period, maximum 3 years after 1st dose
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I
Vienna, Austria
Charité - Universitätsmedizin Berlin, CBF: Campus Benjamin Franklin, CC 14: Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie
Berlin, Germany
Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus
Dresden, Germany
Medizinische Klinik 5 - Hämatologie und Internist. Onkologie, Universitätsklinikum Erlangen
Erlangen, Germany
Medizinische Universitätsklinik, Abt. Innere Medizin I
Freiburg im Breisgau, Germany
Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum
Heidelberg, Germany
Sektion für Stammzell- und Immuntherapie, II. Medizinischen Klinik,
Kiel, Germany
Klinikum rechts der Isar/ Studien / III. Med. Klinik
Munich, Germany
Medizinische Klinik II, Abt. Hämatologie, Onkologie,
Tübingen, Germany
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.